1:45 PM
Jul 11, 2019
 |  BC Extra  |  Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

Editor's Note: This article was updated on Jul 11, 2019 at 4:23 PM PDT

Christi Shaw, SVP and president of Lilly BioMedicines at Eli Lilly and Co. (NYSE:LLY), will step down at the end of August to serve as CEO of the Kite Pharma unit of Gilead Sciences Inc. (NASDAQ:GILD). Shaw, who oversaw the launches of rheumatoid arthritis drug Olumiant baricitinib and migraine drug Emgality galcanezumab-gnlm at Lilly, will be succeeded by Patrik Jonsson, president and general manager of Lilly Japan. The pharma also said SVP...

Read the full 339 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >